CA2503203A1 - Dispositif et procede pour surveiller la migration des leucocytes - Google Patents
Dispositif et procede pour surveiller la migration des leucocytes Download PDFInfo
- Publication number
- CA2503203A1 CA2503203A1 CA002503203A CA2503203A CA2503203A1 CA 2503203 A1 CA2503203 A1 CA 2503203A1 CA 002503203 A CA002503203 A CA 002503203A CA 2503203 A CA2503203 A CA 2503203A CA 2503203 A1 CA2503203 A1 CA 2503203A1
- Authority
- CA
- Canada
- Prior art keywords
- leukocytes
- channel
- well
- mediator
- leukocyte migration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 414
- 230000005012 migration Effects 0.000 title claims abstract description 173
- 238000013508 migration Methods 0.000 title claims abstract description 173
- 238000000034 method Methods 0.000 title claims abstract description 100
- 238000012544 monitoring process Methods 0.000 title claims abstract description 24
- 238000012360 testing method Methods 0.000 claims abstract description 89
- 238000005096 rolling process Methods 0.000 claims description 113
- 210000002889 endothelial cell Anatomy 0.000 claims description 83
- 239000012530 fluid Substances 0.000 claims description 53
- 239000000126 substance Substances 0.000 claims description 37
- 230000003993 interaction Effects 0.000 claims description 36
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 238000004891 communication Methods 0.000 claims description 5
- 230000006854 communication Effects 0.000 claims description 5
- 230000000541 pulsatile effect Effects 0.000 claims description 2
- 238000003556 assay Methods 0.000 abstract description 34
- 210000004204 blood vessel Anatomy 0.000 abstract description 20
- 230000004962 physiological condition Effects 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000009141 biological interaction Effects 0.000 abstract description 3
- 230000003278 mimic effect Effects 0.000 abstract description 3
- 241000182988 Assa Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 105
- 239000003795 chemical substances by application Substances 0.000 description 72
- 210000003038 endothelium Anatomy 0.000 description 59
- 239000000523 sample Substances 0.000 description 55
- 108010035766 P-Selectin Proteins 0.000 description 36
- 102100023472 P-selectin Human genes 0.000 description 36
- 239000003446 ligand Substances 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 27
- 229940098773 bovine serum albumin Drugs 0.000 description 27
- 102000006495 integrins Human genes 0.000 description 23
- 108010044426 integrins Proteins 0.000 description 23
- 108010092694 L-Selectin Proteins 0.000 description 19
- 102000016551 L-selectin Human genes 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 108010024212 E-Selectin Proteins 0.000 description 18
- 102100023471 E-selectin Human genes 0.000 description 18
- 239000002975 chemoattractant Substances 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102100040247 Tumor necrosis factor Human genes 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 17
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 15
- 239000004205 dimethyl polysiloxane Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 14
- 210000000440 neutrophil Anatomy 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000019034 Chemokines Human genes 0.000 description 11
- 108010012236 Chemokines Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 102000003800 Selectins Human genes 0.000 description 10
- 108090000184 Selectins Proteins 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 210000002469 basement membrane Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 230000028709 inflammatory response Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 102100025390 Integrin beta-2 Human genes 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- -1 bradykinins Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 108010067306 Fibronectins Proteins 0.000 description 7
- 102000016359 Fibronectins Human genes 0.000 description 7
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 description 7
- 108010054395 P-selectin ligand protein Proteins 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000002706 hydrostatic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 239000002773 nucleotide Chemical group 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 6
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 5
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 5
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 5
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 5
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000010232 migration assay Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 4
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108010003541 Platelet Activating Factor Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 102000024905 CD99 Human genes 0.000 description 2
- 108060001253 CD99 Proteins 0.000 description 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 2
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000011652 Formyl peptide receptors Human genes 0.000 description 2
- 108010076288 Formyl peptide receptors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 2
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 2
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003229 cytophilic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007459 negative regulation of leukocyte migration Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102100021760 Magnesium transporter protein 1 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 102100022396 Nucleosome assembly protein 1-like 4 Human genes 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 108091007602 SLC58A1 Proteins 0.000 description 1
- 241000801924 Sena Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035926 haptotaxis Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000813 microcontact printing Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5025—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Clinical Laboratory Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Composite Materials (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne un dispositif utilisé pour surveiller la migration des leucocytes, ainsi qu'un procédé d'utilisation de ce dispositif pour surveiller la migration des leucocytes en présence d'un flux de cisaillement physiologique et donc pour simuler les conditions physiologiques d'un vaisseau sanguin in vivo. L'invention concerne également un procédé d'utilisation de ce dispositif pour le criblage à haut débit d'une pluralité d'agents de test. De plus, l'invention concerne un système d'essai flexible et de nombreux essais pouvant être utilisés pour tester des interactions biologiques et des systèmes. Des gradients de flux laminaires sont utilisés pour reproduire des situations de gradient existant in vivo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41997602P | 2002-10-22 | 2002-10-22 | |
| US41998002P | 2002-10-22 | 2002-10-22 | |
| US60/419,980 | 2002-10-22 | ||
| US60/419,976 | 2002-10-22 | ||
| PCT/US2003/033177 WO2004038368A2 (fr) | 2002-10-22 | 2003-10-21 | Dispositif et procede pour surveiller la migration des leucocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2503203A1 true CA2503203A1 (fr) | 2004-05-06 |
Family
ID=32179774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002503186A Abandoned CA2503186A1 (fr) | 2002-10-22 | 2003-10-21 | Tests biologiques utilisant des gradients formes dans des systemes microfluidiques |
| CA002503203A Abandoned CA2503203A1 (fr) | 2002-10-22 | 2003-10-21 | Dispositif et procede pour surveiller la migration des leucocytes |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002503186A Abandoned CA2503186A1 (fr) | 2002-10-22 | 2003-10-21 | Tests biologiques utilisant des gradients formes dans des systemes microfluidiques |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP1558076A4 (fr) |
| JP (2) | JP2006503581A (fr) |
| AU (2) | AU2003287170A1 (fr) |
| CA (2) | CA2503186A1 (fr) |
| WO (2) | WO2004038368A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009035502A1 (de) | 2009-07-30 | 2011-02-03 | Universitätsklinikum Jena | Verfahren und Vorrichtung zur Erfassung der Bewegung und Anlagerung von Zellen und Partikeln an Zell-, Gewebe- und Implantatschichten bei der Simulation von Flussbedingungen |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1773978B1 (fr) * | 2004-05-19 | 2014-04-02 | Massachusetts Institute Of Technology | Modeles de maladie comprenant des tissus/cellules perfuses en trois dimensions |
| US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
| KR100873383B1 (ko) | 2007-11-13 | 2008-12-10 | 이화여자대학교 산학협력단 | 선충의 주화성 연구용 미세 유체 소자 |
| CN103635587A (zh) * | 2008-04-08 | 2014-03-12 | 麻省理工学院 | 三维微流平台和其使用方法 |
| DE102009038520B4 (de) * | 2009-08-25 | 2012-07-05 | Universität Rostock | Verfahren und Vorrichtung zur Zellprobendiagnostik |
| CN102580798B (zh) * | 2012-02-28 | 2014-03-05 | 东北大学 | 一种微流控芯片溶液梯度稀释装置 |
| US9500642B2 (en) * | 2012-04-18 | 2016-11-22 | Hemoshear, Llc | In vitro model for pathological or physiologic conditions |
| JP5910282B2 (ja) * | 2012-04-20 | 2016-04-27 | 大日本印刷株式会社 | 細胞遊走解析方法および細胞培養物作成方法 |
| KR101433091B1 (ko) * | 2012-04-26 | 2014-08-25 | 한국과학기술원 | 박테리아의 주화성 분석용 마이크로 플루이딕 장치, 제조방법 및 이를 이용한 박테리아의 주화성 분석 방법 |
| JP6684706B2 (ja) | 2013-10-21 | 2020-04-22 | ヘモシアー・リミテッド・ライアビリティ・カンパニーＨｅｍｏＳｈｅａｒ， ＬＬＣ | 腫瘍微細環境のための試験管内モデル |
| WO2016065125A1 (fr) * | 2014-10-22 | 2016-04-28 | The General Hospital Corporation | Procédé et appareil de visualisation d'objets à l'aide d'un rétroéclairage oblique |
| CN105080627A (zh) * | 2015-08-25 | 2015-11-25 | 辽宁中医药大学 | 一种用于药物筛选的集成化微流控芯片及其应用方法 |
| CN106497788A (zh) * | 2016-11-28 | 2017-03-15 | 南方医科大学珠江医院 | 体外肝细胞异质性培养装置及其培养方法 |
| JP6931943B2 (ja) | 2017-08-30 | 2021-09-08 | イムプリメド インコーポレイティッドＩｍｐｒｉｍｅｄ，Ｉｎｃ． | 化学的及び生化学的化合物の高処理量選別のための製品 |
| CN111019828B (zh) * | 2019-12-26 | 2021-12-21 | 武汉大学 | 一种开放式高通量微流控卵母细胞动态三维培养芯片及其应用 |
| WO2022070841A1 (fr) * | 2020-09-29 | 2022-04-07 | Nok株式会社 | Appareil de piégeage de leucocytes |
| KR20240134044A (ko) * | 2022-01-28 | 2024-09-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 세포 이동, 화학주성 및 기능을 위한 고 처리량 검정 |
| CN114887034B (zh) * | 2022-07-14 | 2022-10-28 | 中山莱博瑞辰生物医药有限公司 | LLP2A-Ale在制备用于治疗和/或预防外周血淋巴细胞减少症的药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284753A (en) * | 1991-03-20 | 1994-02-08 | Neuro Probe, Inc. | Multiple-site chemotactic test apparatus and method |
| US5460945A (en) * | 1991-05-30 | 1995-10-24 | Center For Blood Research, Inc. | Device and method for analysis of blood components and identifying inhibitors and promoters of the inflammatory response |
| US6632619B1 (en) * | 1997-05-16 | 2003-10-14 | The Governors Of The University Of Alberta | Microfluidic system and methods of use |
| AU734957B2 (en) * | 1997-05-16 | 2001-06-28 | Alberta Research Council Inc. | Microfluidic system and methods of use |
| US6649358B1 (en) * | 1999-06-01 | 2003-11-18 | Caliper Technologies Corp. | Microscale assays and microfluidic devices for transporter, gradient induced, and binding activities |
| US7326563B2 (en) * | 2000-11-08 | 2008-02-05 | Surface Logix, Inc. | Device and method for monitoring leukocyte migration |
| US6699665B1 (en) * | 2000-11-08 | 2004-03-02 | Surface Logix, Inc. | Multiple array system for integrating bioarrays |
| WO2003078565A1 (fr) * | 2002-03-12 | 2003-09-25 | Surface Logix, Inc. | Dispositif pour test de motilite et de chimiotaxie, et son procede d'utilisation |
-
2003
- 2003-10-21 WO PCT/US2003/033177 patent/WO2004038368A2/fr not_active Ceased
- 2003-10-21 WO PCT/US2003/033146 patent/WO2004038367A2/fr not_active Ceased
- 2003-10-21 EP EP03774884A patent/EP1558076A4/fr not_active Withdrawn
- 2003-10-21 EP EP03781348A patent/EP1578194A4/fr not_active Withdrawn
- 2003-10-21 AU AU2003287170A patent/AU2003287170A1/en not_active Abandoned
- 2003-10-21 JP JP2004546913A patent/JP2006503581A/ja active Pending
- 2003-10-21 JP JP2004546909A patent/JP2006507815A/ja active Pending
- 2003-10-21 CA CA002503186A patent/CA2503186A1/fr not_active Abandoned
- 2003-10-21 CA CA002503203A patent/CA2503203A1/fr not_active Abandoned
- 2003-10-21 AU AU2003282950A patent/AU2003282950A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009035502A1 (de) | 2009-07-30 | 2011-02-03 | Universitätsklinikum Jena | Verfahren und Vorrichtung zur Erfassung der Bewegung und Anlagerung von Zellen und Partikeln an Zell-, Gewebe- und Implantatschichten bei der Simulation von Flussbedingungen |
| WO2011012119A1 (fr) | 2009-07-30 | 2011-02-03 | Universitätsklinikum Jena | Procédé et dispositif pour détecter le mouvement et l'agglutination de cellules et de particules sur des couches cellulaires, tissulaires et d'implant lors de la simulation de conditions de circulation physiologique |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004038367A3 (fr) | 2004-11-11 |
| EP1558076A4 (fr) | 2007-03-21 |
| JP2006503581A (ja) | 2006-02-02 |
| EP1558076A2 (fr) | 2005-08-03 |
| WO2004038367A2 (fr) | 2004-05-06 |
| AU2003287170A1 (en) | 2004-05-13 |
| WO2004038368A3 (fr) | 2004-07-29 |
| EP1578194A2 (fr) | 2005-09-28 |
| AU2003282950A1 (en) | 2004-05-13 |
| CA2503186A1 (fr) | 2004-05-06 |
| WO2004038368A2 (fr) | 2004-05-06 |
| JP2006507815A (ja) | 2006-03-09 |
| EP1578194A4 (fr) | 2007-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2503203A1 (fr) | Dispositif et procede pour surveiller la migration des leucocytes | |
| JP7699639B2 (ja) | 分泌物の多細胞アッセイにおけるマイクロ流体デバイスおよびその使用方法 | |
| JP7416749B2 (ja) | 細胞分泌物の分析のための装置及び方法 | |
| US7326563B2 (en) | Device and method for monitoring leukocyte migration | |
| US7374906B2 (en) | Biological assays using gradients formed in microfluidic systems | |
| Primiceri et al. | Cell chips as new tools for cell biology–results, perspectives and opportunities | |
| US8921122B2 (en) | System and method for quantitative assessment of biological migration behavior | |
| CA2484058A1 (fr) | Dispositif et procede destines a controler la migration des leucocytes | |
| US20040178071A1 (en) | Microfluidic system and methods of use | |
| KR20120026551A (ko) | 세포 집단 및 혼합된 세포 집단에서의 변화의 검출 방법 | |
| US20070038384A1 (en) | Devices and assays for monitoring/measuring cellular dynamics to create subject profiles from primary cells | |
| US20060019235A1 (en) | Molecular and functional profiling using a cellular microarray | |
| Bongrand et al. | Studying cell adhesion | |
| Müller | Novel tools for the study of cell type-specific exosomes and microvesicles | |
| Tay et al. | Multiplexed label-free fractionation of peripheral blood mononuclear cells for identification of monocyte–platelet aggregates | |
| US7419823B2 (en) | Device and method for monitoring leukocyte migration | |
| Caserta et al. | A methodology to study chemotaxis in 3‐D collagen gels | |
| US20120058507A1 (en) | Clonal Derivation and Cell Culture quality Control Screening Methods | |
| US20030044766A1 (en) | Methods and devices for detecting cell-cell interactions | |
| US20030044879A1 (en) | Method and device for forming a concentration gradient for chemotactic evaluation through use of laminar flow | |
| AbuElela et al. | Fluorescent multiplex cell rolling assay: Simultaneous capturing up to seven samples in real-time using spectral confocal microscopy | |
| Alapan | Microfabricated Systems Integrated with Biomolecular Probes for Cell Mechanics | |
| Calderwood et al. | 4 In Vitro Techniques to Investigate Lymphocyte Extravasation | |
| Hallila | Experimental work: MONITORING DRUG-CELL INTERACTIONS WITH SURFACE PLASMON RESONANCE TECHNIQUE | |
| Chingozha | New microfluidic systems for single-cell signaling studies in immune cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |